Table 1.
Demographic and baseline characteristics between the treatment groups (ITT population).
| Low-dose Tac group (Group A) (n = 151) |
Standard-dose Tac group (Group B) (n = 141) |
|
|---|---|---|
| Age (years) | 47.7 ± 12.6 | 45.3 ± 12.9 |
| Men (%) | 72.2 | 65.2 |
| Race (%) | ||
| Caucasians | 88.1 | 83.0 |
| Blacks | 4.6 | 10.6 |
| Asians | 4.6 | 3.5 |
| Others | 2.7 | 2.9 |
| Time on dialysis (months) | 30.6 ± 28.4 | 30.4 ± 27.1 |
| Donor/recipient CMV serological status (%) | ||
| Negative/negative | 17.9 | 16.3 |
| Negative/positive | 19.9 | 20.6 |
| Positive/negative | 13.2 | 12.8 |
| Positive/positive | 43.7 | 48.2 |
| Donor age (years) | 42.7 ± 14.1 | 42.0 ± 13.9 |
| Donor type (%) | ||
| Donation after brain death | 69.5 | 67.4 |
| Living related | 18.5 | 23.4 |
| Living unrelated | 11.9 | 9.2 |
| Number of HLA mismatches (%) | ||
| 0 | 2.0 | 2.8 |
| 1–3 | 44.4 | 46.8 |
| 4–6 | 53.6 | 50.4 |
| Cold ischemia time (h) | 13.6 ± 9.1 | 12.0 ± 8.9 |
| PRA < 20% (%) | 97.4 | 98.6 |
CMV: cytomegalovirus; HLA: human leukocyte antigen, PRA: panel reactive antibodies.
Results expressed as mean ± standard deviation (SD) unless otherwise indicated.